Most Recent Stories
More News
Beam Therapeutics (NASDAQ:BEAM) Chief Executive Officer John Evans said the company is advancing its base-editing platform across hematology and liver disease programs, with a potential biologics license...
CAMBRIDGE, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today presented the recently...
The sponsorship helps expand proven strategies to consistently detect a genetic, irreversible, and progressive condition in patients with liver and/or lung disease.
CAMBRIDGE, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John...
CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the...
Recent BEAM-302 Topline Data in Alpha-1 Antitrypsin Deficiency (AATD) Demonstrate Strong Single-dose Safety and Efficacy Profile, with 60 mg Selected as Optimal Biological Dose; Global Pivotal Cohort Expected...
Barchart Research What to Expect from BEAM Earnings BEAM Generated May 4, 2026 Current Price $30.08 EPS Estimate $$-0.87 Consensus Rating Strong Buy Average Move 6.00% Beam Therapeutics Reports Tomorrow,...
Biotech M&A is surging ahead of a $300B patent cliff. Here are 3 gene-editing stocks investors are watching as potential acquisition targets
Prestigious Publication Reinforces risto-cel’s Durable, Differentiated Clinical Data for the Treatment of SCD with Severe Vaso-occlusive Crises (VOCs) Initially Presented at ASH, Data from 31...
Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up...